

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the management of malignant... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1148/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1148" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.">
            <meta name="og:description" content="Read the latest article version by Rodrigo Toledo, Camilo Jimenez, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="15211">
            <meta name="article-id" content="13995">
            <meta name="dc.title" content="Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors">
            <meta name="dc.description" content="Inactivating mutations of the succinate dehydrogenase subunit B ( SDHB ) gene and the subsequent stabilization and activation of the hypoxia-inducible factor 2-alpha (HIF2&alpha;) unit are recognized hallmarks associated with the development of metastatic pheochromocytomas and paragangliomas (MPPG). Despite this discovery, the development of systemic therapies for patients with MPPG has been very slow. The rarity of the disease, the lack of preclinical animal models, and the impracticable development of large clinical trials has hindered the therapeutic progress for MPPG. Chemotherapy and low-specific activity 131 meta-iodo-benzyl-guanidine (MIBG) (manufactured by simple isotope exchange methodology) led to positive clinical responses in about a third of patients. Molecular targeted therapies were introduced into oncological clinical practice at the beginning of the 21st century. These therapies have been demonstrated to be effective for patients with cancers that previously exhibited limited responses to systemic chemotherapy, such as kidney and thyroid carcinomas and pancreatic neuroendocrine tumors. The pathogenesis of MPPG overlaps in some way with the pathogenesis of kidney, medullary thyroid, and pancreatic neuroendocrine carcinomas, providing scientific support to explore molecular targeted therapies such as tyrosine kinase and HIF inhibitors.">
            <meta name="dc.subject" content="Metastatic Pheochromocytoma, Metastatic paraganglioma, tyrosine kinase inhibitors, HIF inhibitors">
            <meta name="dc.creator" content="Toledo, Rodrigo">
            <meta name="dc.creator" content="Jimenez, Camilo">
            <meta name="dc.date" content="2018/07/30">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.13995.1">
            <meta name="dc.source" content="F1000Research 2018 7:1148">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Metastatic Pheochromocytoma">
            <meta name="prism.keyword" content="Metastatic paraganglioma">
            <meta name="prism.keyword" content="tyrosine kinase inhibitors">
            <meta name="prism.keyword" content="HIF inhibitors">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/07/30">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1148">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.13995.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1148">
            <meta name="citation_title" content="Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors">
            <meta name="citation_abstract" content="Inactivating mutations of the succinate dehydrogenase subunit B ( SDHB ) gene and the subsequent stabilization and activation of the hypoxia-inducible factor 2-alpha (HIF2&alpha;) unit are recognized hallmarks associated with the development of metastatic pheochromocytomas and paragangliomas (MPPG). Despite this discovery, the development of systemic therapies for patients with MPPG has been very slow. The rarity of the disease, the lack of preclinical animal models, and the impracticable development of large clinical trials has hindered the therapeutic progress for MPPG. Chemotherapy and low-specific activity 131 meta-iodo-benzyl-guanidine (MIBG) (manufactured by simple isotope exchange methodology) led to positive clinical responses in about a third of patients. Molecular targeted therapies were introduced into oncological clinical practice at the beginning of the 21st century. These therapies have been demonstrated to be effective for patients with cancers that previously exhibited limited responses to systemic chemotherapy, such as kidney and thyroid carcinomas and pancreatic neuroendocrine tumors. The pathogenesis of MPPG overlaps in some way with the pathogenesis of kidney, medullary thyroid, and pancreatic neuroendocrine carcinomas, providing scientific support to explore molecular targeted therapies such as tyrosine kinase and HIF inhibitors.">
            <meta name="citation_description" content="Inactivating mutations of the succinate dehydrogenase subunit B ( SDHB ) gene and the subsequent stabilization and activation of the hypoxia-inducible factor 2-alpha (HIF2&alpha;) unit are recognized hallmarks associated with the development of metastatic pheochromocytomas and paragangliomas (MPPG). Despite this discovery, the development of systemic therapies for patients with MPPG has been very slow. The rarity of the disease, the lack of preclinical animal models, and the impracticable development of large clinical trials has hindered the therapeutic progress for MPPG. Chemotherapy and low-specific activity 131 meta-iodo-benzyl-guanidine (MIBG) (manufactured by simple isotope exchange methodology) led to positive clinical responses in about a third of patients. Molecular targeted therapies were introduced into oncological clinical practice at the beginning of the 21st century. These therapies have been demonstrated to be effective for patients with cancers that previously exhibited limited responses to systemic chemotherapy, such as kidney and thyroid carcinomas and pancreatic neuroendocrine tumors. The pathogenesis of MPPG overlaps in some way with the pathogenesis of kidney, medullary thyroid, and pancreatic neuroendocrine carcinomas, providing scientific support to explore molecular targeted therapies such as tyrosine kinase and HIF inhibitors.">
            <meta name="citation_keywords" content="Metastatic Pheochromocytoma, Metastatic paraganglioma, tyrosine kinase inhibitors, HIF inhibitors">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Rodrigo Toledo">
            <meta name="citation_author_institution" content="Gastrointestinal and Endocrine Tumours Group, Vall d&rsquo;Hebron Institute of Oncology, Barcelona, Spain">
            <meta name="citation_author" content="Camilo Jimenez">
            <meta name="citation_author_institution" content="Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
            <meta name="citation_publication_date" content="2018/07/30">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1148">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.13995.1">
            <meta name="citation_firstpage" content="1148">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1148/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1148.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=15211 /> <input type=hidden id=articleId name=articleId value=13995 /> <input type=hidden id=xmlUrl value="/articles/7-1148/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1148-v1.xml"> <input type=hidden id=article_uuid value=92349a76-407b-4d07-b32e-439e90e854e0 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.13995.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.13995.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1148"
  },
  "headline": "Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase...",
  "datePublished": "2018-07-30T09:36:16",
  "dateModified": "2018-07-30T09:36:16",
  "author": [
    {
      "@type": "Person",
      "name": "Rodrigo Toledo"
    },    {
      "@type": "Person",
      "name": "Camilo Jimenez"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Inactivating mutations of the succinate dehydrogenase subunit B (SDHB) gene and the subsequent stabilization and activation of the hypoxia-inducible factor 2-alpha (HIF2&alpha;) unit are recognized hallmarks associated with the development of metastatic pheochromocytomas and paragangliomas (MPPG). Despite this discovery, the development of systemic therapies for patients with MPPG has been very slow. The rarity of the disease, the lack of preclinical animal models, and the impracticable development of large clinical trials has hindered the therapeutic progress for MPPG. Chemotherapy and low-specific activity 131meta-iodo-benzyl-guanidine (MIBG) (manufactured by simple isotope exchange methodology) led to positive clinical responses in about a third of patients. Molecular targeted therapies were introduced into oncological clinical practice at the beginning of the 21st century. These therapies have been demonstrated to be effective for patients with cancers that previously exhibited limited responses to systemic chemotherapy, such as kidney and thyroid carcinomas and pancreatic neuroendocrine tumors. The pathogenesis of MPPG overlaps in some way with the pathogenesis of kidney, medullary thyroid, and pancreatic neuroendocrine carcinomas, providing scientific support to explore molecular targeted therapies such as tyrosine kinase and HIF inhibitors."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1148/v1",
            "name": "Recent advances in the management of malignant pheochromocytoma and..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the management of malignant pheochromocytoma and... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=15211 data-id=13995 data-downloads="" data-views="" data-scholar="10.12688/f1000research.13995.1" data-recommended="" data-doi="10.12688/f1000research.13995.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1148/v1/pdf?article_uuid=92349a76-407b-4d07-b32e-439e90e854e0" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-13995-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-13995-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-13995-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Toledo R and Jimenez C. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1148 (<a class=new-orange href="https://doi.org/10.12688/f1000research.13995.1" target=_blank>https://doi.org/10.12688/f1000research.13995.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-13995-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=13995 id=track-article-signin-13995 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/13995?target=/articles/7-1148/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15211 /> <input name=articleId type=hidden value=13995 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Rodrigo Toledo<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:cjimenez@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Camilo Jimenez</span></a><a href="https://orcid.org/0000-0002-5292-3355" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-5292-3355</div><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Rodrigo Toledo<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:cjimenez@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Camilo Jimenez</span></a><a href="http://orcid.org/0000-0002-5292-3355" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-5292-3355</div><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 30 Jul 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.13995.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Gastrointestinal and Endocrine Tumours Group, Vall d&rsquo;Hebron Institute of Oncology, Barcelona, Spain<br/> <sup>2</sup> Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA<br/> <p> <div class=margin-bottom> Rodrigo Toledo <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Validation, Visualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Camilo Jimenez <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=27811-36207></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36729-36206></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36730-36205></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Inactivating mutations of the succinate dehydrogenase subunit B (<i>SDHB</i>) gene and the subsequent stabilization and activation of the hypoxia-inducible factor 2-alpha (HIF2) unit are recognized hallmarks associated with the development of metastatic pheochromocytomas and paragangliomas (MPPG). Despite this discovery, the development of systemic therapies for patients with MPPG has been very slow. The rarity of the disease, the lack of preclinical animal models, and the impracticable development of large clinical trials has hindered the therapeutic progress for MPPG. Chemotherapy and low-specific activity <sup>131</sup>meta-iodo-benzyl-guanidine (MIBG) (manufactured by simple isotope exchange methodology) led to positive clinical responses in about a third of patients. Molecular targeted therapies were introduced into oncological clinical practice at the beginning of the 21st century. These therapies have been demonstrated to be effective for patients with cancers that previously exhibited limited responses to systemic chemotherapy, such as kidney and thyroid carcinomas and pancreatic neuroendocrine tumors. The pathogenesis of MPPG overlaps in some way with the pathogenesis of kidney, medullary thyroid, and pancreatic neuroendocrine carcinomas, providing scientific support to explore molecular targeted therapies such as tyrosine kinase and HIF inhibitors. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Metastatic Pheochromocytoma, Metastatic paraganglioma, tyrosine kinase inhibitors, HIF inhibitors </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Camilo Jimenez (<a href="mailto:cjimenez@mdanderson.org">cjimenez@mdanderson.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Camilo Jimenez </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> Rodrigo Toledo is a Miguel Servet-I Investigator (Institute of Health Carlos III) and is supported by a Fundacin Olga Torres Emergent Researcher Grant. Rodrigo Toledo and Camilo Jimenez have received financial research support by a Paradifference Foundation Research Grant. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2018 Toledo R and Jimenez C. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Toledo R and Jimenez C. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1148 (<a href="https://doi.org/10.12688/f1000research.13995.1" target=_blank>https://doi.org/10.12688/f1000research.13995.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Jul 2018, <b>7</b>(F1000 Faculty Rev):1148 (<a href="https://doi.org/10.12688/f1000research.13995.1" target=_blank>https://doi.org/10.12688/f1000research.13995.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 30 Jul 2018, <b>7</b>(F1000 Faculty Rev):1148 (<a href="https://doi.org/10.12688/f1000research.13995.1" target=_blank>https://doi.org/10.12688/f1000research.13995.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d788e180>Introduction</h2><p class="" id=d788e183>Pheochromocytomas and paragangliomas (PPG) are rare neuroendocrine tumors originating in the paraganglia. Pheochromocytomas originate in the adrenal medulla, and paragangliomas originate in the extra-adrenal paraganglia. Most of these tumors secrete excessive amounts of catecholamines that predispose patients to cardiovascular and gastrointestinal morbidity<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. About 15% to 20% of these tumors are metastatic, leading to a decreased overall survival<sup><a href="#ref-3">3</a></sup>. There are no histological, genetic, or molecular markers that could distinguish between benign and malignant disease and subsequently the diagnosis of malignancy relies exclusively on the presence of metastases<sup><a href="#ref-4">4</a></sup>; unfortunately, by then, the disease is usually advanced<sup><a href="#ref-5">5</a></sup>. In fact, only 50% to 60% of patients with metastatic pheochromocytomas and paragangliomas (MPPG) are still alive 5 years after the discovery of metastases<sup><a href="#ref-6">6</a></sup>. Metastases usually involve the lymph nodes (80%), the skeletal tissue (71%), the liver (50%), and the lungs (50%)<sup><a href="#ref-7">7</a></sup>. Whereas some patients succumb to the metastatic tumor burden, others may die because of complications derived from the excessive secretion of catecholamines<sup><a href="#ref-8">8</a></sup>. Currently, there are no systemic therapies approved by the European Medicines Agency or the US Food and Drug Administration (FDA) for patients with MPPG. Treatment options are limited to chemotherapy and low-specific activity <sup>131</sup>meta-iodo-benzyl-guanidine (MIBG) and usually fail to produce a prolonged remission<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>. Furthermore, toxicity associated with chemotherapy and radiopharmaceutical agents cannot be underestimated<sup><a href="#ref-11">11</a></sup>. This scenario illustrates that the identification of clinically effective medications to treat<b></b>MPPG is perhaps the most important unmet clinical need.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e237>Molecular pathogenesis of MPPG</h2><p class="" id=d788e240>The molecular pathogenesis of a substantial number of MPPG was elucidated in the early 2000s, when germline mutations of the succinate dehydrogenase subunit B (<i>SDHB</i>) gene were identified<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>. Since then, the link between <i>SDHB</i> loss and increased risk for MPPG has been validated by several independent studies. It has been determined that about 30% to 40% of patients with MPPG carry a germline mutation of the <i>SDHB</i> gene<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>. These mutations prevent the oxidative catabolism of succinate to fumarate and electron transportation through the internal mitochondrial membrane. Consequently, accumulation of succinate acts as an oncometabolite, leading to stabilization and activation of hypoxia-inducible factors (HIFs), mainly the HIF2-alpha (HIF2) unit<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. Increased expression of HIF2-targeted genes such as the vascular endothelial growth factors (VEGFs) and the platelet-derived growth factor beta (PDGF-) and their receptors is observed in <i>SDHB</i> MPPG as well as many apparently sporadic tumors<sup><a href="#ref-18">18</a></sup>. In addition, genes involved in glucose metabolism, such as the hexokinase 2 and lactate dehydrogenase genes, are also upregulated<sup><a href="#ref-18">18</a></sup>. Activation of all of these genes leads to abnormally increased angiogenesis and cell growth, decreased apoptosis, and increased glucose uptake<sup><a href="#ref-19">19</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e292>Challenges in the discovery of new medications to treat MPPG</h2><p class="" id=d788e295>Although the genetic causes of many MPPG (mainly <i>SDHB</i> mutations) and the molecular events leading to the metastatic transformation of chromaffin cells (stabilization and activation of HIF2, DNA hypermethylation)<sup><a href="#ref-20">20</a></sup> were determined several years ago, the development of therapeutics against MPPG has been very slow for three main reasons: (a) difficulty of patient enrollment in large clinical trials, (b) lack of preclinical animal models, and (c) lack of efficient, targeted drugs. Given the rarity of MPPG (estimated incidence is less than one per million people per year), it is almost impossible to have multiple clinical trials testing a variety of drugs or drug combinations concomitantly. Several knockout mouse models for <i>SDHB</i> and other pheochromocytoma- and paraganglioma-related genes leading to activation of HIF2 (that is, von Hippel-Lindau and the mitochondrial enzymatic complex II subunit D genes) have not been demonstrated to mimic the human phenotype<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>. The lack of a reliable preclinical animal model is a major drawback that has impaired the screening of available drugs and drug combinations. Subsequently, the design of effective clinical trials relies mainly on clinical observations and increases the risk of wasting time and effort on trials that yield little or no benefit for patients with MPPG<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. Moreover, the lack of animal models makes it very difficult to identify mechanisms of resistance that would enable the design of trials that combine therapies that could concomitantly or sequentially tackle escape pathways, prolonging clinical benefits. Therefore, clinical scientists and pharmaceutical research have prioritized their efforts on the few most promising medications to ensure sufficient patient enrollment. These difficulties have resulted in very slow progress and circumscribed therapeutic improvements.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e325>Tyrosine kinase inhibitors under evaluation in clinical trials</h2><p class="" id=d788e328>Several tyrosine kinase inhibitors (TKIs), including axitinib, cabozantinib, lenvatinib, pazopanib, and sunitinib, are currently under evaluation in phase II clinical trials (<a target=xrefwindow href="https://www.clinicaltrials.gov/" id=d788e330>www.ClinicalTrials.gov</a>). These agents have in common their capacity to block the activation of the VEGF receptors (VEGFRs), preventing angiogenesis and cell growth<sup><a href="#ref-25">25</a></sup> (<a href="#f1">Figure 1</a>). In addition, TKIs can inhibit other tyrosine kinase receptors that are universally involved in processes such as cancer cell growth, tumor spread, and development of resistance<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup> (<a href="#f1">Figure 1</a>). Compelling positive results derived from phase III clinical trials have led to their approval by regulatory agencies for the treatment of malignancies such as kidney, thyroid, and pancreatic neuroendocrine carcinomas. Of interest, the pathogenesis of these tumors frequently overlaps with the pathogenesis of MPPG, supporting the development of clinical trials for MPPG. A historical description of preliminary clinical findings in MPPG treated with these medications follows.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15211/9a7345eb-b4d1-4400-88b2-88b0b14a668c_figure1.gif"><img alt="9a7345eb-b4d1-4400-88b2-88b0b14a668c_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15211/9a7345eb-b4d1-4400-88b2-88b0b14a668c_figure1.gif"></a><div class=caption><h3>Figure 1. Pharmacodynamics of tyrosine kinase and hypoxia-inducible factor 2 inhibitors under evaluation in clinical trials for patients with metastatic pheochromocytomas and paragangliomas.</h3><p id=d788e361>This figure includes information on the mechanism of action of systemic chemotherapy and radiopharmaceutical agents: <sup>131</sup>meta-iodo-benzyl-guanidine (MIBG) and <sup>177</sup>Lu-DOTATATE.</p></div></div><div class=section><a name=d788e374 class=n-a></a><h3 class=section-title>1. Sunitinib</h3><p class="" id=d788e379>Sunitinib was the first TKI described as a possibly effective treatment for patients with MPPG. Sunitinib was approved for the treatment of advanced kidney cancer on the basis of the impressive results derived from a phase III clinical trial<sup><a href="#ref-28">28</a></sup>. In 2008, two simultaneous case reports described potential benefits derived from sunitinib. In a patient with MPPG in the context of von Hippel-Lindau disease, sunitinib was associated with tumor size reduction and blood pressure and pain control. The decision to study sunitinib in this patient was supported by the demonstration of a very high expression of VEGF and PDGFRB-1 in the removed primary tumor and the simultaneous presentation of progressive multifocal kidney cancer for which sunitinib was indicated<sup><a href="#ref-29">29</a></sup>. In another case report, the discovery of benefits derived from sunitinib was accidental. The patient presented with a large unresectable mass suspicious of kidney cancer; the patient received sunitinib and the tumor became resectable. Surprisingly, histological evaluation confirmed a paraganglioma<sup><a href="#ref-30">30</a></sup>. Over time, several MPPG patients who were not candidates or responsive to chemotherapy/MIBG received sunitinib. In a retrospective intention-to-treat analysis of 17 patients who received sunitinib, 47% exhibited partial responses and disease stabilization with blood pressure control despite catecholamine excess. Positive responses were noticed in carriers of <i>SDHB</i> mutations as well as patients with apparently sporadic tumors. Progression-free survival was only 4.1 months; 23.5% of patients discontinued therapy because of adverse events such as overwhelming fatigue, pain exacerbation, hand and foot syndrome, and cardiovascular disease (severe hypertension and syncope)<sup><a href="#ref-31">31</a></sup>. Two phase II clinical trials with sunitinib are ongoing (<a target=xrefwindow href="https://www.clinicaltrials.gov/" id=d788e401>www.ClinicalTrials.gov</a>).</p></div><div class=section><a name=d788e406 class=n-a></a><h3 class=section-title>2. Pazopanib</h3><p class="" id=d788e411>The mechanism of action of pazopanib overlaps with that of sunitinib; like sunitinib, pazopanib is approved for the treatment of patients with kidney cancer. Some studies in kidney cancer previously suggested that pazopanib could be an easier medication to tolerate than sunitinib<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>. A phase II clinical trial for MPPG with pazopanib was subsequently developed. The primary endpoint of the trial was best objective response rate. Intervention was pazopanib 400 mg daily for 2 weeks followed by dose titration to 800 mg daily. The trial recruited seven patients. Only one patient exhibited a confirmed partial response that lasted for about 2 years. Several patients had overwhelming side effects: 17% had grade 34 diarrhea, hematuria, headaches, and fatigue, and 50% had severe hypertension<sup><a href="#ref-34">34</a></sup>. Toxicity was more obvious after doubling the dose of pazopanib. The trial was terminated because of lack of recruitment.</p></div><div class=section><a name=d788e427 class=n-a></a><h3 class=section-title>3. Axitinib</h3><p class="" id=d788e432>Axitinib is a pure anti-angiogenic medication. As it only blocks the VEGFR, it may be associated with fewer adverse events when compared with sunitinib and pazopanib<sup><a href="#ref-35">35</a></sup>. Axitinib is also approved for the treatment of kidney cancer. However, experience with axitinib in patients with kidney cancer has demonstrated that hypertension might be a difficult problem to face during treatment<sup><a href="#ref-36">36</a></sup>. A phase II clinical trial for MPPG was developed. The trial recruited 11 patients. The primary endpoint was objective response rate. Intervention was axitinib 5 mg twice dose with dose titration to 7.510 mg twice a day; 36% of patients achieved a partial response. Severe hypertension was noticed in 82% of patients and dose could not be titrated up. Conversely, all patients required dose reduction<sup><a href="#ref-37">37</a></sup>. The trial is currently closed for recruitment.</p></div><div class=section><a name=d788e448 class=n-a></a><h3 class=section-title>4. Cabozantinib</h3><p class="" id=d788e453>Cabozantinib is perhaps the most potent anti-angiogenic medication currently approved for the treatment of cancer<sup><a href="#ref-38">38</a></sup>. In addition to inhibiting the VEGFRs, cabozantinib inhibits the c-met receptor pathways which are involved in tumor growth and spread and the development of resistance to anti-angiogenesis<sup><a href="#ref-38">38</a></sup>. Cabozantinib is approved for the treatment of medullary thyroid and kidney cancers<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup> and seems to be more effective than sunitinib in advanced kidney cancer<sup><a href="#ref-41">41</a></sup>. A phase II clinical trial with cabozantinib is ongoing. The trial is expected to recruit 22 patients. The primary endpoint is objective response rate. Intervention is cabozantinib 60 mg daily. Unlike the previously described clinical trials, the trial with cabozantinib allows dose titration down to 40 and 20 mg, as clinical observations in patients with other cancers have demonstrated positive responses despite the dose reduction. Preliminary results derived from 14 patients who received cabozantinib reveal that 93% of them have exhibited partial responses or disease stabilization with some degree of regression<sup><a href="#ref-42">42</a></sup>. To date, the clinical trial has not reported grade 4 or 5 adverse events. Two patients presented with grade 3 adverse events; these events were an asymptomatic elevation of pancreatic enzymes and a rectal fistula that was corrected with surgery. Hypertension, mainly grade 1, has been noticed in 40% of patients<sup><a href="#ref-42">42</a></sup>. The trial includes an exploratory branch for patients with predominant bone metastases. The trial is actively recruiting patients.</p></div><div class=section><a name=d788e485 class=n-a></a><h3 class=section-title>5. Lenvatinib</h3><p class="" id=d788e490>Lenvatinib is another potent anti-angiogenic medication. It also inhibits the fibroblast growth factor receptor pathway. Lenvatinib is approved for the treatment of advanced thyroid cancer of follicular origin<sup><a href="#ref-43">43</a></sup> and has demonstrated clinical effectiveness in medullary thyroid cancer<sup><a href="#ref-44">44</a></sup>. Lenvatinib in combination with everolimus is also approved for the treatment of kidney cancer<sup><a href="#ref-45">45</a></sup>. Isolated clinical experience suggested that this medication may have a positive impact on MPPG. A phase II clinical trial with lenvatinib is looking at objective response rate as the primary endpoint. This trial recently initiated recruitment (<a target=xrefwindow href="https://www.clinicaltrials.gov/" id=d788e504>www.ClinicalTrials.gov</a>).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e512>Tyrosine kinase inhibitors and cardiovascular events in patients with MPPG</h2><p class="" id=d788e515>Preliminary results of several clinical trials show that several TKIs with mainly anti-angiogenic activity may cause anti-tumor effects in a substantial number of patients with MPPG<sup><a href="#ref-31">31</a>,<a href="#ref-34">34</a></sup>. However, effectiveness has been undermined by cardiovascular events<sup><a href="#ref-34">34</a></sup>. It is important to recognize that MPPG are indeed more difficult to treat than other cancers given the endocrine nature of the disease. Most patients with MPPG are found with a large tumor burden<sup><a href="#ref-3">3</a></sup>. Furthermore, the majority of these tumors secrete excessive amounts of catecholamines, mainly noradrenaline. Therefore, patients with MPPG have an elevated risk for severe cardiovascular disease upon exposure to systemic therapies such as TKIs. Hypertension and cardiovascular disease may be caused by a combination of medication, direct cardiovascular toxicity (that is, inhibition of nitric oxide synthesis)<sup><a href="#ref-46">46</a></sup>, or the rapid and massive release of catecholamines once the tumor destruction starts. Guidelines on how to treat MPPG are not existent. Nevertheless, treatment with alpha- and beta-blockers should be offered to all patients with catecholamine-secreting PPG<sup><a href="#ref-1">1</a>,<a href="#ref-47">47</a></sup>. Alpha-blockers should be started first and titrated as soon as possible in order to achieve orthostatism and allow the initiation of the beta-blockers to protect the heart<sup><a href="#ref-1">1</a></sup>. Alpha- and beta-blockers could be titrated to very high doses (that is, doxazosin 16 mg daily; propranolol 640 mg daily)<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>; nevertheless, concerns related to high-dose toxicity and lack of effectiveness have been raised. Therefore, patients frequently need the addition of other anti-hypertensive drugs such as calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, labetalol, hydralazine, or catecholamine synthesis inhibitors (metyrosine) or a combination of these<sup><a href="#ref-50">50</a></sup>. In fact, studies have shown that patients with MPPG may need an average of four to six anti-hypertensive drugs in order to normalize their blood pressure. The clinical trials have shown that the doses of different TKIs must be carefully chosen. As suggested by the preliminary results of the cabozantinib phase II study, it is always better to choose a starting dose that is clearly associated with clinical benefits and that allows dose titration down, preserving effectiveness. This approach may allow one to later titrate the dose up once an anti-tumor effect is achieved, as catecholamine secretion may have already decreased by then. In the meantime, anti-hypertensive doses should be adjusted accordingly. Acute complications are not uncommon, and treating physicians and principal investigators must be familiar with the treatment of hypertensive crisis with medications such as nitroprusside, nicardipine, and esmolol. It is also important to remember that patients with MPPG may have easier-to-control blood pressure after primary tumor resection (if possible) because of a decreased catecholamine surge<sup><a href="#ref-51">51</a></sup>. Surgery of the primary tumor and solitary metastasis should be considered before any systemic therapy is instituted.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e568>Tyrosine kinase inhibitors and other drug-related adverse events</h2><p class="" id=d788e571>Patients who receive TKIs frequently complain of constitutional symptoms, hand and foot syndrome, pain exacerbation, and gastrointestinal irritability among other symptoms. Treating physicians must be familiar with these potential side effects and beforehand should establish therapeutic interventions that could prevent exacerbation of these symptoms to guarantee a successful treatment. These interventions may includebut are not limited tothe use of moisturizer lotions to prevent dryness, avoidance of overuse of hands and feet, and adjustment of analgesic doses before initiation of therapy to prevent pain exacerbation in patients with bone metastases. Constipation is an uncommon but sometimes difficult complication in patients with MPPG<sup><a href="#ref-2">2</a></sup>. TKIs frequently cause diarrhea. Although this adverse event could benefit patients with constipation, our clinical experience indicates that it is better to treat the constipation with other interventions before a molecular targeted therapy is started. Symptoms such as nausea, vomiting, and abdominal pain could be severe in constipated patients who receive targeted therapies<sup><a href="#ref-52">52</a></sup>; these symptoms may prevent patients from taking systemic therapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e585>Anti-angiogenic TKIs inhibit part of the HIF2 pathway</h2><p class="" id=d788e588>As described above, treatment of MPPG with anti-angiogenic TKIs can lead to partial responses and stable disease; however, such treatments may have limited long-term benefits, since patients developed subsequent resistance and progression<sup><a href="#ref-31">31</a></sup>. One plausible explanation for this is that while these drugs inhibit mainly the angiogenic pathway through VEGFRs, the observed progression and resistance may be related to the compensatory activation of HIF2 molecular pathways caused by hypoxia induced by blood vessel regression<sup><a href="#ref-53">53</a></sup>.</p><p class="" id=d788e599>Robust molecular studies have identified HIF2 as one of the main oncogenic drivers of paraganglioma/pheochromocytoma (PPGL)<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>. In addition to <i>SDHB</i> mutations leading to HIF2 activation, mutations in the HIF2-encoding gene (<i>EPAS1</i>) have been identified and functionally characterized in PPGL<sup><a href="#ref-56">56</a></sup>. These validated findings, implicating the disruption of genes involved in the response to hypoxia, have spearheaded the initiation of therapeutic strategies to directly tackle HIF2 (<a href="#f1">Figure 1</a>).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e625>Development of first-in-class HIF2 inhibitors</h2><p class="" id=d788e628>For many years, transcription factors, including HIF2, were considered undruggable, and pharmaceutical research focused mainly on the HIF pathway downstream (that is, VEGFR2). In 2009, the structure of a heterodimer between the HIF2 PAS (Per-ARNT-Sim) domainswhich sensor oxygen and REDOX potentialand ARNT was solved by crystallography, enabling the identification of a large protein cavity located within the HIF2 PAS-B domain. Such a bulky cavity, which is extremely rare in proteins, was expected to accommodate small molecules and therefore to be successfully targeted. Based on the structure of the HIF2:ARNT protein dimer, an extensive screening of small-molecule libraries has been performed and identified specific HIF2 inhibitors with potential for clinical development.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e634>HIF2 inhibitors show low toxicity and high clinical efficiency in human hypoxic tumors</h2><p class="" id=d788e637>HIF2 inhibitors have shown tumor inhibition in both <i>in vitro</i> and <i>in vivo</i> models of clear cell renal cell carcinomas (RCCs) associated with pseudo-hypoxia<sup><a href="#ref-57">57</a></sup>. The results of a clinical trial with a HIF2 inhibitor in patients with locally advanced or metastatic RCC that progressed with at least one prior systemic therapy revealed complete responses, partial responses, and stable disease in 2%, 12%, and 52% of heavily pretreated patients, respectively. Of interest, no patients discontinued treatment because of adverse events<sup><a href="#ref-58">58</a></sup>. Further studies are required to determine whether such promising HIF2 antagonists will be effective for the treatment of MPPG.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e657>Other molecular targeted therapies</h2><p class="" id=d788e660>In addition to the tyrosine kinase and HIF2 inhibitors, there are molecular targeted therapies that have or may have a positive impact in MPPG. These therapies include radiopharmaceutical medications such as high-specific activity MIBG and peptide receptor radionuclide therapy (PRRT). The final results of the phase II clinical trial with high-specific activity MIBG (Azedra<sup></sup>) for MPPG that express the cell membrane catecholamine-uptake transporter are impressive; more than 90% of patients exhibit clinical benefits<sup><a href="#ref-59">59</a></sup>. This medication has received breakthrough therapy designation by the FDA, and the clinical results are currently under evaluation by this regulatory agency. PRRT was recently approved for the treatment of gastroenteropancreatic neuroendocrine tumors that express cell membrane somatostatin receptors<sup><a href="#ref-60">60</a></sup>. MPPG frequently express somatostatin receptors in the cell membrane; subsequently, these patients may benefit from PRRT<sup><a href="#ref-61">61</a></sup>. A phase II clinical trial with <sup>177</sup>Lu-DOTATATE was recently activated (<a target=xrefwindow href="https://www.clinicaltrials.gov/" id=d788e681>www.ClinicalTrials.gov</a>). As the focus of this article is on tyrosine kinase and HIF2 inhibitors, we will not discuss these therapies further.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d788e688>Conclusions</h2><p class="" id=d788e691>Observations derived from phase II clinical trials with tyrosine kinase and HIF inhibitors have revealed anti-neoplastic effects. However, it is important to recognize that MPPG are more challenging to treat when compared with other oncological conditions that are also treated with these medications. Their large tumor burden and their frequently overwhelming hormonal manifestations may lead to a high rate of adverse events. Clinical trials must be carefully designed and should actively involve clinicians familiar with the endocrine manifestations of MPPG. Results of several clinical trials with TKIs are still preliminary, and we cannot yet define the therapeutic role that these medications might have in MPPG. HIF2 inhibitors may target the core of the MPPG pathogenesis and, together with cabozantinib, are perhaps some of the most exciting medications to explore in MPPG. As expected, tyrosine kinase and HIF inhibitors could control but alone cannot cure advanced MPPG. Therefore, the research effort to understand the pathogenesis of MPPG must continue, as it is clearly helping to identify potential therapies. This effort will help us to recognize medications with unique and fundamental mechanisms of action that, when used alone or especially in combination, may finally help to conquer this orphan and devastating disease.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d788e1 class=n-a></a><h2 class=main-title id=d983>Competing interests</h2><p class=metadata-entry><a name=d788e106 class=n-a></a><p id=d788e107> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d788e1 class=n-a></a><h2 class=main-title id=d985>Grant information</h2><p>Rodrigo Toledo is a Miguel Servet-I Investigator (Institute of Health Carlos III) and is supported by a Fundacin Olga Torres Emergent Researcher Grant. Rodrigo Toledo and Camilo Jimenez have received financial research support by a Paradifference Foundation Research Grant.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i></p></div><div class=back-section><a name=d788e698 class=n-a></a><h2 class=main-title id=d788e700>Acknowledgments</h2><p class="" id=d788e703>Camilo Jimenez would like to acknowledge Ms Natalie Papadam, Mr Peter Liu, the Team Nat Foundation, Ms Margaret Cazalot, Ms Marle Granek, and Dr Catherine Cotten for their immense support in developing clinical trials for patients with malignant pheochromocytomas and paragangliomas.</p></div><div class=back-section><a name=d788e707 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d1180>References</h2><div class="section ref-list"><a name=d788e707 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718431045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e714 class=n-a></a>Lenders JW, Duh QY, Eisenhofer G, <i> et al.</i>: Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab.</i> 2014; <b>99</b>(6): 191542. <a target=xrefwindow id=d788e725 href="http://www.ncbi.nlm.nih.gov/pubmed/24893135">PubMed Abstract </a> | <a target=xrefwindow id=d788e728 href="http://dx.doi.org/10.1210/jc.2014-1498">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718431045">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d788e741 class=n-a></a>Thosani S, Ayala-Ramirez M, Romn-Gonzlez A, <i> et al.</i>: Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. <i>Eur J Endocrinol.</i> 2015; <b>173</b>(3): 37787. <a target=xrefwindow id=d788e752 href="http://www.ncbi.nlm.nih.gov/pubmed/26060051">PubMed Abstract </a> | <a target=xrefwindow id=d788e755 href="http://dx.doi.org/10.1530/EJE-15-0456">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d788e764 class=n-a></a>Ayala-Ramirez M, Feng L, Johnson MM, <i> et al.</i>: Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. <i>J Clin Endocrinol Metab.</i> 2011; <b>96</b>(3): 71725. <a target=xrefwindow id=d788e775 href="http://www.ncbi.nlm.nih.gov/pubmed/21190975">PubMed Abstract </a> | <a target=xrefwindow id=d788e778 href="http://dx.doi.org/10.1210/jc.2010-1946">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727612517"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e787 class=n-a></a>Lam AK: Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. <i>Endocr Pathol.</i> 2017; <b>28</b>(3): 21327. <a target=xrefwindow id=d788e795 href="http://www.ncbi.nlm.nih.gov/pubmed/28477311">PubMed Abstract </a> | <a target=xrefwindow id=d788e798 href="http://dx.doi.org/10.1007/s12022-017-9484-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727612517">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729975670"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e811 class=n-a></a>Roman-Gonzalez A, Jimenez C: Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials. <i>Curr Opin Endocrinol Diabetes Obes.</i> 2017; <b>24</b>(3): 17483. <a target=xrefwindow id=d788e819 href="http://www.ncbi.nlm.nih.gov/pubmed/28234804">PubMed Abstract </a> | <a target=xrefwindow id=d788e822 href="http://dx.doi.org/10.1097/MED.0000000000000330">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729975670">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d788e836 class=n-a></a>Jimenez C, Rohren E, Habra MA, <i> et al.</i>: Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. <i>Curr Oncol Rep.</i> 2013; <b>15</b>(4): 35671. <a target=xrefwindow id=d788e847 href="http://www.ncbi.nlm.nih.gov/pubmed/23674235">PubMed Abstract </a> | <a target=xrefwindow id=d788e850 href="http://dx.doi.org/10.1007/s11912-013-0320-x">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d788e859 class=n-a></a>Baudin E, Habra MA, Deschamps F, <i> et al.</i>: Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. <i>Eur J Endocrinol.</i> 2014; <b>171</b>(3): R11122. <a target=xrefwindow id=d788e870 href="http://www.ncbi.nlm.nih.gov/pubmed/24891137">PubMed Abstract </a> | <a target=xrefwindow id=d788e873 href="http://dx.doi.org/10.1530/EJE-14-0113">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d788e882 class=n-a></a>Jimenez P, Tatsui C, Jessop A, <i> et al.</i>: Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress. <i>Curr Oncol Rep.</i> 2017; <b>19</b>(12): 83. <a target=xrefwindow id=d788e893 href="http://www.ncbi.nlm.nih.gov/pubmed/29081018">PubMed Abstract </a> | <a target=xrefwindow id=d788e896 href="http://dx.doi.org/10.1007/s11912-017-0643-0">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d788e905 class=n-a></a>Niemeijer ND, Alblas G, van Hulsteijn LT, <i> et al.</i>: Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. <i>Clin Endocrinol (Oxf).</i> 2014; <b>81</b>(5): 64251. <a target=xrefwindow id=d788e916 href="http://www.ncbi.nlm.nih.gov/pubmed/25041164">PubMed Abstract </a> | <a target=xrefwindow id=d788e919 href="http://dx.doi.org/10.1111/cen.12542">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d788e928 class=n-a></a>van Hulsteijn LT, Niemeijer ND, Dekkers OM, <i> et al.</i>: <sup>131</sup>I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. <i>Clin Endocrinol (Oxf).</i> 2014; <b>80</b>(4): 487501. <a target=xrefwindow id=d788e942 href="http://www.ncbi.nlm.nih.gov/pubmed/24118038">PubMed Abstract </a> | <a target=xrefwindow id=d788e946 href="http://dx.doi.org/10.1111/cen.12341">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d788e955 class=n-a></a>Ayala-Ramirez M, Feng L, Habra MA, <i> et al.</i>: Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. <i>Cancer.</i> 2012; <b>118</b>(11): 280412. <a target=xrefwindow id=d788e966 href="http://www.ncbi.nlm.nih.gov/pubmed/22006217">PubMed Abstract </a> | <a target=xrefwindow id=d788e969 href="http://dx.doi.org/10.1002/cncr.26577">Publisher Full Text </a> | <a target=xrefwindow id=d788e973 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3882190">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d788e983 class=n-a></a>Astuti D, Latif F, Dallol A, <i> et al.</i>: Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. <i>Am J Hum Genet.</i> 2001; <b>69</b>(1): 4954. <a target=xrefwindow id=d788e994 href="http://www.ncbi.nlm.nih.gov/pubmed/11404820">PubMed Abstract </a> | <a target=xrefwindow id=d788e997 href="http://dx.doi.org/10.1086/321282">Publisher Full Text </a> | <a target=xrefwindow id=d788e1001 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1226047">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1015808"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1010 class=n-a></a>Gimenez-Roqueplo A, Favier J, Rustin P, <i> et al.</i>: Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. <i>Cancer Res.</i> 2003; <b>63</b>(17): 561521. <a target=xrefwindow id=d788e1021 href="http://www.ncbi.nlm.nih.gov/pubmed/14500403">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1015808">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d788e1034 class=n-a></a>Amar L, Baudin E, Burnichon N, <i> et al.</i>: Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. <i>J Clin Endocrinol Metab.</i> 2007; <b>92</b>(10): 38228. <a target=xrefwindow id=d788e1045 href="http://www.ncbi.nlm.nih.gov/pubmed/17652212">PubMed Abstract </a> | <a target=xrefwindow id=d788e1048 href="http://dx.doi.org/10.1210/jc.2007-0709">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d788e1057 class=n-a></a>Pasini B, Stratakis CA: SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. <i>J Intern Med.</i> 2009; <b>266</b>(1): 1942. <a target=xrefwindow id=d788e1065 href="http://www.ncbi.nlm.nih.gov/pubmed/19522823">PubMed Abstract </a> | <a target=xrefwindow id=d788e1068 href="http://dx.doi.org/10.1111/j.1365-2796.2009.02111.x">Publisher Full Text </a> | <a target=xrefwindow id=d788e1071 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3163304">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d788e1080 class=n-a></a>Dahia PL: Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. <i>Nat Rev Cancer.</i> 2014; <b>14</b>(2): 10819. <a target=xrefwindow id=d788e1088 href="http://www.ncbi.nlm.nih.gov/pubmed/24442145">PubMed Abstract </a> | <a target=xrefwindow id=d788e1091 href="http://dx.doi.org/10.1038/nrc3648">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1022674"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1100 class=n-a></a>Selak MA, Armour SM, MacKenzie ED, <i> et al.</i>: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. <i>Cancer Cell.</i> 2005; <b>7</b>(1): 7785. <a target=xrefwindow id=d788e1111 href="http://www.ncbi.nlm.nih.gov/pubmed/15652751">PubMed Abstract </a> | <a target=xrefwindow id=d788e1114 href="http://dx.doi.org/10.1016/j.ccr.2004.11.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1022674">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1028550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1128 class=n-a></a>Dahia PL, Ross KN, Wright ME, <i> et al.</i>: A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. <i>PLoS Genet.</i> 2005; <b>1</b>(1): 7280. <a target=xrefwindow id=d788e1139 href="http://www.ncbi.nlm.nih.gov/pubmed/16103922">PubMed Abstract </a> | <a target=xrefwindow id=d788e1142 href="http://dx.doi.org/10.1371/journal.pgen.0010008">Publisher Full Text </a> | <a target=xrefwindow id=d788e1146 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1183527">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1028550">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725232277"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1159 class=n-a></a>Favier J, Amar L, Gimenez-Roqueplo A: Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. <i>Nat Rev Endocrinol.</i> 2015; <b>11</b>(2): 10111. <a target=xrefwindow id=d788e1167 href="http://www.ncbi.nlm.nih.gov/pubmed/25385035">PubMed Abstract </a> | <a target=xrefwindow id=d788e1170 href="http://dx.doi.org/10.1038/nrendo.2014.188">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725232277">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718013617"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1183 class=n-a></a>Letouz E, Martinelli C, Loriot C, <i> et al.</i>: SDH mutations establish a hypermethylator phenotype in paraganglioma. <i>Cancer Cell.</i> 2013; <b>23</b>(6): 73952. <a target=xrefwindow id=d788e1194 href="http://www.ncbi.nlm.nih.gov/pubmed/23707781">PubMed Abstract </a> | <a target=xrefwindow id=d788e1197 href="http://dx.doi.org/10.1016/j.ccr.2013.04.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718013617">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725600381"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1210 class=n-a></a>Lepoutre-Lussey C, Thibault C, Buffet A, <i> et al.</i>: From <i>Nf1</i> to <i>Sdhb</i> knockout: Successes and failures in the quest for animal models of pheochromocytoma. <i>Mol Cell Endocrinol.</i> 2016; <b>421</b>: 408. <a target=xrefwindow id=d788e1228 href="http://www.ncbi.nlm.nih.gov/pubmed/26123588">PubMed Abstract </a> | <a target=xrefwindow id=d788e1231 href="http://dx.doi.org/10.1016/j.mce.2015.06.027">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725600381">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732635806"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1244 class=n-a></a>Lussey-Lepoutre C, Buffet A, Morin A, <i> et al.</i>: Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis. <i>Cell Tissue Res.</i> 2018; <b>372</b>(2): 37992. <a target=xrefwindow id=d788e1255 href="http://www.ncbi.nlm.nih.gov/pubmed/29427052">PubMed Abstract </a> | <a target=xrefwindow id=d788e1258 href="http://dx.doi.org/10.1007/s00441-018-2797-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732635806">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d788e1271 class=n-a></a>Oh D, Kim T, Park YS, <i> et al.</i>: Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. <i>Cancer.</i> 2012; <b>118</b>(24): 616270. <a target=xrefwindow id=d788e1282 href="http://www.ncbi.nlm.nih.gov/pubmed/22736481">PubMed Abstract </a> | <a target=xrefwindow id=d788e1285 href="http://dx.doi.org/10.1002/cncr.27675">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d788e1295 class=n-a></a>Park SR, Speranza G, Piekarz R, <i> et al.</i>: A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. <i>Cancer Chemother Pharmacol.</i> 2013; <b>71</b>(4): 98190. <a target=xrefwindow id=d788e1306 href="http://www.ncbi.nlm.nih.gov/pubmed/23404627">PubMed Abstract </a> | <a target=xrefwindow id=d788e1309 href="http://dx.doi.org/10.1007/s00280-013-2091-3">Publisher Full Text </a> | <a target=xrefwindow id=d788e1313 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4457312">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727451434"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1322 class=n-a></a>Roskoski R Jr: Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. <i>Pharmacol Res.</i> 2017; <b>120</b>: 11632. <a target=xrefwindow id=d788e1330 href="http://www.ncbi.nlm.nih.gov/pubmed/28330784">PubMed Abstract </a> | <a target=xrefwindow id=d788e1333 href="http://dx.doi.org/10.1016/j.phrs.2017.03.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727451434">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d788e1346 class=n-a></a>McCormack PL: Pazopanib: a review of its use in the management of advanced renal cell carcinoma. <i>Drugs.</i> 2014; <b>74</b>(10): 111125. <a target=xrefwindow id=d788e1354 href="http://www.ncbi.nlm.nih.gov/pubmed/24935162">PubMed Abstract </a> | <a target=xrefwindow id=d788e1357 href="http://dx.doi.org/10.1007/s40265-014-0243-3">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727062030"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1366 class=n-a></a>Al-Salama ZT, Keating GM: Cabozantinib: A Review in Advanced Renal Cell Carcinoma. <i>Drugs.</i> 2016; <b>76</b>(18): 17718. <a target=xrefwindow id=d788e1374 href="http://www.ncbi.nlm.nih.gov/pubmed/27909994">PubMed Abstract </a> | <a target=xrefwindow id=d788e1377 href="http://dx.doi.org/10.1007/s40265-016-0661-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727062030">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1088476"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1390 class=n-a></a>Motzer RJ, Hutson TE, Tomczak P, <i> et al.</i>: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. <i>N Engl J Med.</i> 2007; <b>356</b>(2): 11524. <a target=xrefwindow id=d788e1401 href="http://www.ncbi.nlm.nih.gov/pubmed/17215529">PubMed Abstract </a> | <a target=xrefwindow id=d788e1404 href="http://dx.doi.org/10.1056/NEJMoa065044">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1088476">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d788e1417 class=n-a></a>Jimenez C, Cabanillas ME, Santarpia L, <i> et al.</i>: Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. <i>J Clin Endocrinol Metab.</i> 2009; <b>94</b>(2): 38691. <a target=xrefwindow id=d788e1428 href="http://www.ncbi.nlm.nih.gov/pubmed/19017755">PubMed Abstract </a> | <a target=xrefwindow id=d788e1431 href="http://dx.doi.org/10.1210/jc.2008-1972">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d788e1441 class=n-a></a>Joshua AM, Ezzat S, Asa SL, <i> et al.</i>: Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. <i>J Clin Endocrinol Metab.</i> 2009; <b>94</b>(1): 59. <a target=xrefwindow id=d788e1452 href="http://www.ncbi.nlm.nih.gov/pubmed/19001511">PubMed Abstract </a> | <a target=xrefwindow id=d788e1455 href="http://dx.doi.org/10.1210/jc.2008-1836">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717956434"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1464 class=n-a></a>Ayala-Ramirez M, Chougnet CN, Habra MA, <i> et al.</i>: Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. <i>J Clin Endocrinol Metab.</i> 2012; <b>97</b>(11): 404050. <a target=xrefwindow id=d788e1475 href="http://www.ncbi.nlm.nih.gov/pubmed/22965939">PubMed Abstract </a> | <a target=xrefwindow id=d788e1478 href="http://dx.doi.org/10.1210/jc.2012-2356">Publisher Full Text </a> | <a target=xrefwindow id=d788e1482 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3683800">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717956434">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718083271"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1495 class=n-a></a>Motzer RJ, Hutson TE, Cella D, <i> et al.</i>: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. <i>N Engl J Med.</i> 2013; <b>369</b>(8): 72231. <a target=xrefwindow id=d788e1506 href="http://www.ncbi.nlm.nih.gov/pubmed/23964934">PubMed Abstract </a> | <a target=xrefwindow id=d788e1509 href="http://dx.doi.org/10.1056/NEJMoa1303989">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718083271">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d788e1522 class=n-a></a>Escudier B, Porta C, Bono P, <i> et al.</i>: Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. <i>J Clin Oncol.</i> 2014; <b>32</b>(14): 14128. <a target=xrefwindow id=d788e1533 href="http://www.ncbi.nlm.nih.gov/pubmed/24687826">PubMed Abstract </a> | <a target=xrefwindow id=d788e1536 href="http://dx.doi.org/10.1200/JCO.2013.50.8267">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d788e1545 class=n-a></a>Jasim S, Suman VJ, Jimenez C, <i> et al.</i>: Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. <i>Endocrine.</i> 2017; <b>57</b>(2): 2205. <a target=xrefwindow id=d788e1556 href="http://www.ncbi.nlm.nih.gov/pubmed/28685225">PubMed Abstract </a> | <a target=xrefwindow id=d788e1559 href="http://dx.doi.org/10.1007/s12020-017-1359-5">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d788e1568 class=n-a></a>Keating GM: Axitinib: a review in advanced renal cell carcinoma. <i>Drugs.</i> 2015; <b>75</b>(16): 190313. <a target=xrefwindow id=d788e1576 href="http://www.ncbi.nlm.nih.gov/pubmed/26487541">PubMed Abstract </a> | <a target=xrefwindow id=d788e1579 href="http://dx.doi.org/10.1007/s40265-015-0483-x">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726493915"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1589 class=n-a></a>Wang H, Man L, Li G, <i> et al.</i>: Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis. <i>Onco Targets Ther.</i> 2016; <b>9</b>: 342332. <a target=xrefwindow id=d788e1600 href="http://www.ncbi.nlm.nih.gov/pubmed/27354814">PubMed Abstract </a> | <a target=xrefwindow id=d788e1603 href="http://dx.doi.org/10.2147/OTT.S100706">Publisher Full Text </a> | <a target=xrefwindow id=d788e1607 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4907737">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726493915">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d788e1620 class=n-a></a>Burotto Pichun ME, Edgerly M, Velarde M, <i> et al.</i>: Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P/PG): Preliminary results. <i>JCO.</i> 2015; <b>33</b>(7): 457. <a target=xrefwindow id=d788e1631 href="http://dx.doi.org/10.1200/jco.2015.33.7_suppl.457">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d788e1640 class=n-a></a>Hoy SM: Cabozantinib: a review of its use in patients with medullary thyroid cancer. <i>Drugs.</i> 2014; <b>74</b>(12): 143544. <a target=xrefwindow id=d788e1648 href="http://www.ncbi.nlm.nih.gov/pubmed/25056653">PubMed Abstract </a> | <a target=xrefwindow id=d788e1651 href="http://dx.doi.org/10.1007/s40265-014-0265-x">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725809299"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1660 class=n-a></a>Choueiri TK, Escudier B, Powles T, <i> et al.</i>: Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>N Engl J Med.</i> 2015; <b>373</b>(19): 181423. <a target=xrefwindow id=d788e1671 href="http://www.ncbi.nlm.nih.gov/pubmed/26406150">PubMed Abstract </a> | <a target=xrefwindow id=d788e1674 href="http://dx.doi.org/10.1056/NEJMoa1510016">Publisher Full Text </a> | <a target=xrefwindow id=d788e1678 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5024539">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725809299">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718098672"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1691 class=n-a></a>Elisei R, Schlumberger MJ, Mller SP, <i> et al.</i>: Cabozantinib in progressive medullary thyroid cancer. <i>J Clin Oncol.</i> 2013; <b>31</b>(29): 363946. <a target=xrefwindow id=d788e1702 href="http://www.ncbi.nlm.nih.gov/pubmed/24002501">PubMed Abstract </a> | <a target=xrefwindow id=d788e1705 href="http://dx.doi.org/10.1200/JCO.2012.48.4659">Publisher Full Text </a> | <a target=xrefwindow id=d788e1709 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4164813">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718098672">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727316145"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1722 class=n-a></a>Choueiri TK, Halabi S, Sanford BL, <i> et al.</i>: Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>J Clin Oncol.</i> 2017; <b>35</b>(6): 5917. <a target=xrefwindow id=d788e1733 href="http://www.ncbi.nlm.nih.gov/pubmed/28199818">PubMed Abstract </a> | <a target=xrefwindow id=d788e1736 href="http://dx.doi.org/10.1200/JCO.2016.70.7398">Publisher Full Text </a> | <a target=xrefwindow id=d788e1740 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5455807">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727316145">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d788e1754 class=n-a></a>Jimenez C, Waguespack S, Habra MA, <i> et al.</i>: A Phase 2 Clinical Trial with Cabozantinib for Patients with Malignant Pheochromocytoma and Paraganglioma: Preliminary Results. The University of Texas MD Anderson Cancer Center, Oral Presentation, Global Academic Programs Symposium, Houston, Texas. 2017. </span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725353054"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1766 class=n-a></a>Schlumberger M, Tahara M, Wirth LJ, <i> et al.</i>: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. <i>N Engl J Med.</i> 2015; <b>372</b>(7): 62130. <a target=xrefwindow id=d788e1777 href="http://www.ncbi.nlm.nih.gov/pubmed/25671254">PubMed Abstract </a> | <a target=xrefwindow id=d788e1780 href="http://dx.doi.org/10.1056/NEJMoa1406470">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725353054">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725749411"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1793 class=n-a></a>Schlumberger M, Jarzab B, Cabanillas ME, <i> et al.</i>: A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. <i>Clin Cancer Res.</i> 2016; <b>22</b>(1): 4453. <a target=xrefwindow id=d788e1804 href="http://www.ncbi.nlm.nih.gov/pubmed/26311725">PubMed Abstract </a> | <a target=xrefwindow id=d788e1807 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-1127">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725749411">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d788e1820 class=n-a></a>Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer. <i>Clin Adv Hematol Oncol.</i> 2015; <b>13</b>(8): 5123. <a target=xrefwindow id=d788e1828 href="http://www.ncbi.nlm.nih.gov/pubmed/26351813">PubMed Abstract </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732734762"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1837 class=n-a></a>Totzeck M, Mincu RI, Mrotzek S, <i> et al.</i>: Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients. <i>Eur J Prev Cardiol.</i> 2018; <b>25</b>(5): 48294. <a target=xrefwindow id=d788e1848 href="http://www.ncbi.nlm.nih.gov/pubmed/29376753">PubMed Abstract </a> | <a target=xrefwindow id=d788e1851 href="http://dx.doi.org/10.1177/2047487318755193">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732734762">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733648681"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1864 class=n-a></a>Gu YW, Poste J, Kunal M, <i> et al.</i>: Cardiovascular Manifestations of Pheochromocytoma. <i>Cardiol Rev.</i> 2017; <b>25</b>(5): 21522. <a target=xrefwindow id=d788e1875 href="http://www.ncbi.nlm.nih.gov/pubmed/28786897">PubMed Abstract </a> | <a target=xrefwindow id=d788e1878 href="http://dx.doi.org/10.1097/CRD.0000000000000141">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733648681">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d788e1892 class=n-a></a>Achari R, Hosmane B, Bonacci E, <i> et al.</i>: The relationship between terazosin dose and blood pressure response in hypertensive patients. <i>J Clin Pharmacol.</i> 2000; <b>40</b>(10): 116672. <a target=xrefwindow id=d788e1903 href="http://www.ncbi.nlm.nih.gov/pubmed/11028256">PubMed Abstract </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d788e1912 class=n-a></a>Prys-Roberts C, Farndon JR: Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. <i>World J Surg.</i> 2002; <b>26</b>(8): 103742. <a target=xrefwindow id=d788e1920 href="http://www.ncbi.nlm.nih.gov/pubmed/12192533">PubMed Abstract </a> | <a target=xrefwindow id=d788e1923 href="http://dx.doi.org/10.1007/s00268-002-6667-z">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d788e1932 class=n-a></a>Plouin PF, Fitzgerald P, Rich T, <i> et al.</i>: Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. <i>Horm Metab Res.</i> 2012; <b>44</b>(5): 3909. <a target=xrefwindow id=d788e1943 href="http://www.ncbi.nlm.nih.gov/pubmed/22314389">PubMed Abstract </a> | <a target=xrefwindow id=d788e1946 href="http://dx.doi.org/10.1055/s-0031-1299707">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d788e1955 class=n-a></a>Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, <i> et al.</i>: Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. <i>Ann Surg.</i> 2018; <b>268</b>(1): 1728. <a target=xrefwindow id=d788e1966 href="http://www.ncbi.nlm.nih.gov/pubmed/28257320">PubMed Abstract </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733648682"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e1975 class=n-a></a>Li J, Gu J: Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. <i>Eur J Clin Pharmacol.</i> 2017; <b>73</b>(10): 120917. <a target=xrefwindow id=d788e1983 href="http://www.ncbi.nlm.nih.gov/pubmed/28710508">PubMed Abstract </a> | <a target=xrefwindow id=d788e1986 href="http://dx.doi.org/10.1007/s00228-017-2299-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733648682">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d788e1999 class=n-a></a>Toledo RA: New HIF2 inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas. <i>Endocr Relat Cancer.</i> 2017; <b>24</b>(9): C9C19. <a target=xrefwindow id=d788e2007 href="http://www.ncbi.nlm.nih.gov/pubmed/28667082">PubMed Abstract </a> | <a target=xrefwindow id=d788e2010 href="http://dx.doi.org/10.1530/ERC-16-0479">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1022932"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e2020 class=n-a></a>Rathmell WK, Hickey MM, Bezman NA, <i> et al.</i>: <i>In vitro</i> and <i>in vivo</i> models analyzing von Hippel-Lindau disease-specific mutations. <i>Cancer Res.</i> 2004; <b>64</b>(23): 8595603. <a target=xrefwindow id=d788e2038 href="http://www.ncbi.nlm.nih.gov/pubmed/15574766">PubMed Abstract </a> | <a target=xrefwindow id=d788e2041 href="http://dx.doi.org/10.1158/0008-5472.CAN-04-1430">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1022932">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d788e2054 class=n-a></a>Favier J, Igaz P, Burnichon N, <i> et al.</i>: Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. <i>Endocr Pathol.</i> 2012; <b>23</b>(1): 3442. <a target=xrefwindow id=d788e2065 href="http://www.ncbi.nlm.nih.gov/pubmed/22183643">PubMed Abstract </a> | <a target=xrefwindow id=d788e2068 href="http://dx.doi.org/10.1007/s12022-011-9189-0">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d788e2077 class=n-a></a>Toledo RA, Qin Y, Srikantan S, <i> et al.</i>: <i>In vivo</i> and <i>in vitro</i> oncogenic effects of <i>HIF2A</i> mutations in pheochromocytomas and paragangliomas. <i>Endocr Relat Cancer.</i> 2013; <b>20</b>(3): 34959. <a target=xrefwindow id=d788e2098 href="http://www.ncbi.nlm.nih.gov/pubmed/23533246">PubMed Abstract </a> | <a target=xrefwindow id=d788e2101 href="http://dx.doi.org/10.1530/ERC-13-0101">Publisher Full Text </a> | <a target=xrefwindow id=d788e2104 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5944295">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726713697"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e2113 class=n-a></a>Chen W, Hill H, Christie A, <i> et al.</i>: Targeting renal cell carcinoma with a HIF-2 antagonist. <i>Nature.</i> 2016; <b>539</b>(7627): 1127. <a target=xrefwindow id=d788e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/27595394">PubMed Abstract </a> | <a target=xrefwindow id=d788e2127 href="http://dx.doi.org/10.1038/nature19796">Publisher Full Text </a> | <a target=xrefwindow id=d788e2131 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5340502">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726713697">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732326989"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e2144 class=n-a></a>Courtney KD, Infante JR, Lam ET, <i> et al.</i>: Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>J Clin Oncol.</i> 2018; <b>36</b>(9): 86774. <a target=xrefwindow id=d788e2155 href="http://www.ncbi.nlm.nih.gov/pubmed/29257710">PubMed Abstract </a> | <a target=xrefwindow id=d788e2158 href="http://dx.doi.org/10.1200/JCO.2017.74.2627">Publisher Full Text </a> | <a target=xrefwindow id=d788e2162 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5946714">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732326989">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d788e2175 class=n-a></a>Jimenez C, Chin BB, Noto RB, <i> et al.</i>: AZEDRA (iobenguane I 131) in patients with metastatic and/or recurrent and/or unresectable pheochromocytoma or paraganglioma: Results of a multicenter, open-label, pivotal phase 2b study. Paper presented at the NANETS, Philadelphia, Pennsylvania. 2017. <a target=xrefwindow id=d788e2180 href="https://nanets.net/abstracts-archive/2017/549-c28-azedra-iobenguane-i-131-in-patients-with-malignant-and-or-recurrent-pheochromocytoma-paraganglioma-ppgl-final-results-of-a-multi-center-open-label-pivotal-phase-2b-study/file">Reference Source</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727194330"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d788e2190 class=n-a></a>Strosberg J, El-Haddad G, Wolin E, <i> et al.</i>: Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine Tumors. <i>N Engl J Med.</i> 2017; <b>376</b>(2): 12535. <a target=xrefwindow id=d788e2204 href="http://www.ncbi.nlm.nih.gov/pubmed/28076709">PubMed Abstract </a> | <a target=xrefwindow id=d788e2208 href="http://dx.doi.org/10.1056/NEJMoa1607427">Publisher Full Text </a> | <a target=xrefwindow id=d788e2211 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5895095">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727194330">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d788e2224 class=n-a></a>Maurice JB, Troke R, Win Z, <i> et al.</i>: A comparison of the performance of <sup>68</sup>Ga-DOTATATE PET/CT and <sup>123</sup>I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. <i>Eur J Nucl Med Mol Imaging.</i> 2012; <b>39</b>(8): 126670. <a target=xrefwindow id=d788e2242 href="http://www.ncbi.nlm.nih.gov/pubmed/22526961">PubMed Abstract </a> | <a target=xrefwindow id=d788e2245 href="http://dx.doi.org/10.1007/s00259-012-2119-7">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Jul 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1148/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1148/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Gastrointestinal and Endocrine Tumours Group, Vall d&rsquo;Hebron Institute of Oncology, Barcelona, Spain<br/> <sup>2</sup> Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA<br/> <p> <div class=margin-bottom> Rodrigo Toledo <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Validation, Visualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Camilo Jimenez <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1148/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Jul 2018, 7:1148 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.13995.1">https://doi.org/10.12688/f1000research.13995.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2018 Toledo R and Jimenez C. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=15211 data-id=13995 data-downloads="" data-views="" data-scholar="10.12688/f1000research.13995.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1148/v1/pdf?article_uuid=92349a76-407b-4d07-b32e-439e90e854e0" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.13995.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Toledo R and Jimenez C. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors [version 1; peer review: 3 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1148 (<a href="https://doi.org/10.12688/f1000research.13995.1" target=_blank>https://doi.org/10.12688/f1000research.13995.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=13995 id=mobile-track-article-signin-13995 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/13995?target=/articles/7-1148/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15211 /> <input name=articleId type=hidden value=13995 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Judith Favier</strong>, INSERM, UMR970, Paris-Centre de Recherche Cardiovasculaire, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Carmen C. Sol&oacute;rzano</strong>, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>David Ta&iuml;eb</strong>, Department of Nuclear Medicine, La Timone University Hospital, France; European Center for Research in Medical Imaging, Aix-Marseille University, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Jul 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1148/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1148/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=27811-36207></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36729-36206></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36730-36205></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1148/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Jul 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Judith Favier</strong>, INSERM, UMR970, Paris-Centre de Recherche Cardiovasculaire, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Carmen C. Sol&oacute;rzano</strong>, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>David Ta&iuml;eb</strong>, Department of Nuclear Medicine, La Timone University Hospital, France; European Center for Research in Medical Imaging, Aix-Marseille University, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1148/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1148/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the management of malignant...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1148/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1148/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1148/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Toledo R and Jimenez C');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1148/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1148",
            templates : {
                twitter : "Recent advances in the management of malignant pheochromocytoma.... Toledo R and Jimenez C, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1148/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/13995/15211")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "15211");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "36205": 0,
                           "36206": 0,
                           "36207": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "f001548d-8ce3-43c0-a4e3-7a7620707a10";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1148.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1148.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1148.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1148.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1148.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>